HIGHLIGHTS
- who: I.C. Kok from the Departments of Medical OncologyDepartments of Medical Oncology have published the article: 89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer, in the Journal: (JOURNAL) of 27/01/2021
- what: The authors carried out a study with zirconium-89 (89Zr)-pembrolizumab in patients with locally advanced or metastatic melanoma and NSCLC. The authors report the SUVmax for tumor lesions and the SUVmean for normal organ 89Zr-pembrolizumab uptake. From these models, the authors report geometric mean SUVmax values and corresponding 95 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.